Paper18596265
Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.
Tran-Lundmark K and 9 others. Circ Res, 2008. Cited by 87 papers, by iCite.
Cite this record
ConductScience Library. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Papers, record 18596265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18596265
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apolipoproteins E | Major topic |
| Atherosclerosis | Major topic |
| Capillary Permeability | Major topic |
| Heparan Sulfate Proteoglycans | Major topic |
| Heparan Sulfate | Major topic |
| Myocytes, Smooth Muscle | Major topic |
| Triglycerides | Major topic |
| Actins | |
| Animals | |
| Antigens, CD | |
| Antigens, Differentiation, Myelomonocytic | |
| Aorta | |
| Apolipoproteins B | |
| Cell Proliferation | |
| Crosses, Genetic | |
| Disease Models, Animal | |
| Humans | |
| Inflammation | |
| Lipoproteins, LDL | |
| Mice | |
| Mice, Knockout | |
| Protein Binding | |
| CD68 Molecule |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 HL018645 | NHLBI NIH HHS | United States | P01HL018645 | PubMed and NIH | NIH RePORTER |
| 18645 | PHS HHS | United States | PubMed | PubMed |
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16011323 | Heparan sulfate: a complex polymer charged with biological activity. | Chem Rev | 2005 | https://conductscience.org/library/papers/16011323 | PubMed |
| 2 | 9020150 | Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. | J Biol Chem | 1997 | https://conductscience.org/library/papers/9020150 | PubMed |
| 3 | 14726411 | Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. | Arterioscler Thromb Vasc Biol | 2004 | https://conductscience.org/library/papers/14726411 | PubMed |
| 4 | 7159490 | Acidic glycosaminoglycan, lipid and water contents in human coronary arterial branches. | Atherosclerosis | 1982 | https://conductscience.org/library/papers/7159490 | PubMed |
| 5 | 12066187 | Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. | Nature | 2002 | https://conductscience.org/library/papers/12066187 | PubMed |
| 6 | 11739273 | CD40 signaling and plaque instability. | Circ Res | 2001 | https://conductscience.org/library/papers/11739273 | PubMed |
| 7 | 8530367 | Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. | J Biol Chem | 1995 | https://conductscience.org/library/papers/8530367 | PubMed |
| 8 | 9719326 | Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. | J Vasc Surg | 1998 | https://conductscience.org/library/papers/9719326 | PubMed |
| 9 | 11884291 | Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. | Arterioscler Thromb Vasc Biol | 2002 | https://conductscience.org/library/papers/11884291 | PubMed |
| 10 | 859561 | Suppression by heparin of smooth muscle cell proliferation in injured arteries. | Nature | 1977 | https://conductscience.org/library/papers/859561 | PubMed |
| 11 | 15258195 | Atherosclerosis in perlecan heterozygous mice. | J Lipid Res | 2004 | https://conductscience.org/library/papers/15258195 | PubMed |
| 12 | 16221765 | Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16221765 | PubMed |
| 13 | 11122703 | Lipid mediators that modulate the extracellular matrix structure and function in vascular cells. | Curr Atheroscler Rep | 1999 | https://conductscience.org/library/papers/11122703 | PubMed |
| 14 | 15186946 | Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. | Atherosclerosis | 2004 | https://conductscience.org/library/papers/15186946 | PubMed |
| 15 | 12514129 | Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. | EMBO J | 2003 | https://conductscience.org/library/papers/12514129 | PubMed |
| 16 | 9259586 | Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. | J Clin Invest | 1997 | https://conductscience.org/library/papers/9259586 | PubMed |
| 17 | 9988721 | Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein e. | J Biol Chem | 1999 | https://conductscience.org/library/papers/9988721 | PubMed |
| 18 | 10600481 | Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. | Biochem Biophys Res Commun | 1999 | https://conductscience.org/library/papers/10600481 | PubMed |
| 19 | 6324731 | Measurement in vivo of irreversible degradation of low density lipoprotein in the rabbit aorta. Predominance of intimal degradation. | Arteriosclerosis | 1984 | https://conductscience.org/library/papers/6324731 | PubMed |
| 20 | 15117408 | Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. | Cardiovasc Diabetol | 2004 | https://conductscience.org/library/papers/15117408 | PubMed |
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41408231 | Arterial collagen IV and laminin levels associate with type 2 diabetes, glycemic control, major adverse cardiac events, and mortality in coronary bypass patients. | Cardiovasc Diabetol | 2025 | https://conductscience.org/library/papers/41408231 | PubMed |
| 40146858 | Modulation of host gene expression by the zinc finger antiviral protein. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40146858 | PubMed |
| 39743565 | Apolipoprotein B-containing lipoproteins in atherogenesis. | Nat Rev Cardiol | 2025 | https://conductscience.org/library/papers/39743565 | PubMed |
| 39167826 | Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosis. | Cardiovasc Res | 2024 | https://conductscience.org/library/papers/39167826 | PubMed |
| 38141085 | Mechano-chemo-biological model of atherosclerosis formation based on the outside-in theory. | Biomech Model Mechanobiol | 2024 | https://conductscience.org/library/papers/38141085 | PubMed |
| 37587506 | Knowledge fields and emerging trends about extracellular matrix in carotid artery disease from 1990 to 2021: analysis of the scientific literature. | Eur J Med Res | 2023 | https://conductscience.org/library/papers/37587506 | PubMed |
| 36986536 | Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/36986536 | PubMed |
| 36140217 | Heparan Sulfate: A Regulator of White Adipocyte Differentiation and of Vascular/Adipocyte Interactions. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140217 | PubMed |
| 35887981 | TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. | J Clin Med | 2022 | https://conductscience.org/library/papers/35887981 | PubMed |
| 35795646 | Smooth Muscle Cell-Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location. | Front Physiol | 2022 | https://conductscience.org/library/papers/35795646 | PubMed |
| 35163259 | The Role of Matrix Proteins in Cardiac Pathology. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163259 | PubMed |
| 34626401 | Methods to Analyze the Effect of Diet-Derived Metabolites on Endothelial Inflammation and Cell Surface Glycosaminoglycans. | Methods Mol Biol | 2022 | https://conductscience.org/library/papers/34626401 | PubMed |
| 34433968 | APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. | Nature | 2021 | https://conductscience.org/library/papers/34433968 | PubMed |
| 34200914 | Potential Benefits of Flavonoids on the Progression of Atherosclerosis by Their Effect on Vascular Smooth Muscle Excitability. | Molecules | 2021 | https://conductscience.org/library/papers/34200914 | PubMed |
| 34105546 | The interaction of chondroitin sulfate with a lipid monolayer observed by using nonlinear vibrational spectroscopy. | Phys Chem Chem Phys | 2021 | https://conductscience.org/library/papers/34105546 | PubMed |
| 33817084 | Aberrant DNA Methylation Involved in Obese Women with Systemic Insulin Resistance. | Open Life Sci | 2018 | https://conductscience.org/library/papers/33817084 | PubMed |
| 33684447 | Macrophages bind LDL using heparan sulfate and the perlecan protein core. | J Biol Chem | 2021 | https://conductscience.org/library/papers/33684447 | PubMed |
| 33494649 | A Systems View of the Heparan Sulfate Interactome. | J Histochem Cytochem | 2021 | https://conductscience.org/library/papers/33494649 | PubMed |
| 33344181 | Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy. | Int J Ophthalmol | 2020 | https://conductscience.org/library/papers/33344181 | PubMed |
| 33340050 | Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis. | Handb Exp Pharmacol | 2022 | https://conductscience.org/library/papers/33340050 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| BGN | 633 | PubTator's text mining | https://conductscience.org/library/genes/633 | NCBI Gene |
| VCAN | 1462 | PubTator's text mining | https://conductscience.org/library/genes/1462 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18596265
GET https://conductscience.org/api/papers/v1/18596265/references?page=2